Message #26 From:
NewsBot Date: January 5, 2007 04:00:00 AM
XKEM News Amalfi Research Group Releases Research Report on Xechem International, Inc.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM) announced today that
Amalfi Research Group, Ltd. has recently completed a research report on
the company. The entire comprehensive report and other relevant company
information can be viewed at http://www.xkem.octrader.net
or call 1-800-277-9081 for additional information. Amalfi Research
Group, Ltd. is a provider of market intelligence, analytical reports,
and strategic advisory services for the capital markets, with primary
focus on emerging small cap organizations.
About Xechem
Xechem International is a development stage biopharmaceutical company
working on Sickle Cell Disease (SCD), antidiabetic, antimalarial,
antibacterial, antifungal, anticancer and antiviral (including AIDS)
products from natural sources, including microbial and marine organisms.
Its focus is on the development of phyto-pharmaceuticals (Natural Herbal
Drugs) and other proprietary technologies, including those used in the
treatment of orphan diseases. Xechem’s mission
is to bring relief to the millions of people who suffer from these
diseases. Its recent focus and resources have been directed primarily
toward the development and launch of NICOSAN™
(to be marketed as HEMOXIN™ in the US and
Europe). With the Nigerian regulatory approval now in hand, Xechem is
now working on the commercialization of the drug in Nigeria and the
pursuit of US FDA and European regulatory approval. In addition to
NICOSAN™, Xechem is also working on another
sickle cell compound, 5-HMF, which it has licensed from Virginia
Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as amended,
which are intended to be covered by safe harbors created hereby.Such
forward-looking statements involve known and unknown risks and
uncertainties.
